DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2246063/astrazeneca-s-azn-ultomiris-gets-fda-nod-for-new-indication?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2246063 Mar 26, 2024 - FDA approves AstraZeneca's (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved for this rare neurological disease. 0

https://www.zacks.com/stock/news/2247400/pharma-stock-roundup-abbv-nvo-s-new-m-as-fda-nod-to-jnj-mrk-pah-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-2247400 Mar 28, 2024 - While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs. 0

https://www.fool.com/investing/2024/03/28/bull-market-buys-3-dividend-stocks-to-own-for-the/?source=iedfolrf0000001 Mar 28, 2024 - Invest in stability, dividends, and growth with these three accomplished real estate operators. 0

https://www.zacks.com/stock/news/2249245/are-you-looking-for-a-high-growth-dividend-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-2249245 Apr 02, 2024 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out. 0

https://www.zacks.com/stock/news/2253429/nurix-nrix-up-on-upbeat-initial-data-from-phase-i-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253429 Apr 10, 2024 - Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies. 0

https://www.zacks.com/stock/news/2254638/astrazeneca-s-azn-fasenra-gets-fda-nod-for-asthma-in-kids?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2254638 Apr 12, 2024 - The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years. 0